Overview

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation

Status:
Completed
Trial end date:
2003-10-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Asia, Europe and Oceania. The aim of this trial is to evaluate the efficacy of placebo and activated recombinant human factor VII in patients having undergone allogeneic or autologous stem cell transplantation.
Phase:
Phase 2
Details
Lead Sponsor:
Novo Nordisk A/S